Desai, M. Y., Owens, A., Wolski, K., Geske, J. B., Saberi, S., Wang, A., … VALOR-HCM Investigators. (2024). Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial. J Am Coll Cardiol, 84(11), 1041–1045. https://doi.org/10.1016/j.jacc.2024.06.025

Desai, Milind Y., Anjali Owens, Kathy Wolski, Jeffrey B. Geske, Sara Saberi, Andrew Wang, Mark Sherrid, et al. “Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.” J Am Coll Cardiol 84, no. 11 (September 10, 2024): 1041–45. https://doi.org/10.1016/j.jacc.2024.06.025.

Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, et al. Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial. J Am Coll Cardiol. 2024 Sep 10;84(11):1041–5.

Desai, Milind Y., et al. “Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.” J Am Coll Cardiol, vol. 84, no. 11, Sept. 2024, pp. 1041–45. Pubmed, doi:10.1016/j.jacc.2024.06.025.

Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Zhong Y, Wyrwich KW, Lampl KL, Sehnert AJ, Nissen SE, Spertus JA, VALOR-HCM Investigators. Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial. J Am Coll Cardiol. 2024 Sep 10;84(11):1041–1045.